Vosoritide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and HAS (France) recommended or restricted vosoritide, while CONITEC (Brazil), DMC (Denmark) and NYE METODER (Norway), among others, did not recommend it.
The record spans 4.6 years, opening at HAS (France) on 15 Dec 2021 and running to 3 Jul 2026.
PBAC (Australia) changed its position: not recommended in 2022, recommended by 2022, after a resubmission.
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand), AWMSG (Wales) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 10 of 14 records date from 2023 or later.
Against its own class, vosoritide is an outlier: 54% of its decisive outcomes were positive, where molecules sharing ATC class M05B average 75%.
3 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess vosoritide, on 15 Dec 2021; CONITEC (Brazil) did not open a file until 3 Jul 2026 — a wide spread of 4.6 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 6 years in total.
5 of the 8 agencies here assessed vosoritide more than once, PBAC (Australia) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for vosoritide.
The full ledger for vosoritide reads 6 not recommended, 5 recommended, 2 restricted and 1 deferred.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 3 Jul 2026 | Tratamento de acondroplasia em pacientes a partir de 2 anos de idade e cujas epífises não estão fechadas. | not incorporated | source |
| AIFA (Italy) | 27 Oct 2025 | VOXZOGO è indicato nel trattamento dell’acondroplasia in pazienti di età compresa tra i 4 mesi e i 14 anni al momento de… | fully innovative, since expired | source |
| NYE METODER (Norway) | 18 Jun 2025 | Behandling av akondroplasi hos pasienter som er 2 år og eldre, der epifysen ikke er lukket. Diagnosen akondroplasi skal … | not introduced | source |
| HAS (France) | 12 Feb 2025 | Indication extension | SMR low · ASMR V | source |
| G-BA (Germany) | 16 May 2024 | Voxzogo — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
9 further decisions for vosoritide, across 7 agencies, are not shown here. They include the most recent record on file, 3 Jul 2026 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- denosumab — same ATC class M05B — Bone diseases
- burosumab — same ATC class M05B — Bone diseases
- romosozumab — same ATC class M05B — Bone diseases
- zoledronic acid — same ATC class M05B — Bone diseases
- dibotermin alfa — same ATC class M05B — Bone diseases
- ibandronic acid — same ATC class M05B — Bone diseases
Coverage: 14 decisions for vosoritide from 8 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class M05B — Bone diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.